NSABP B-64

NSABP B-64

Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease

Target Accrual: 1800 patients

Status: Not Recruiting

ClinicialTrials.gov Identifier: